Antipsychotics for depression: An acceptable risk/benefit profile

Clinical Question: Are antipsychotics, either added to standard antidepressants or as monotherapy, effective for the treatment of depression without psychotic features?

Evidence:

2010 Cochrane review (28 trials, 8487 patients)
- Antipsychotic versus antidepressant: Equivalence is uncertain
  - Olanzapine (5 trials, 779 patients): 2 of 5 olanzapine studies found antidepressants superior (3 found no difference)
  - Quetiapine (1 trial, 309): equivalent but only one trial.
- Antipsychotic versus placebo: Only quetiapine (4 trials, 2069 patients) was studied in depression without psychosis.
  - Response Number Needed to Treat (NNT) 8 and remission NNT 17.
- Antipsychotic added to (augmenting) antidepressants: 12 trials using aripiprazole, olanzapine, quetiapine, or risperidone
  - Response NNT 7-12, and remission NNT 7-12.
- Adverse events were common, and typical of the antipsychotic studied (example 4kg weight gain with olanzapine).
  - More patients stopped due to adverse events in the antipsychotic group: Number Needed to Harm (NNH) 6-13 when used alone and NNH 12-50 when used as augmentation.
- Insufficient evidence to determine if one antipsychotic is superior to others.

Context:

- Trials in the systematic review have a high risk of bias including unclear allocation concealment, selective reporting and short trial duration (22 of 28 studies <12 weeks)
  - Although not assessed, selective publication (not publishing negative studies) and sponsorship bias, are common concerns in the literature.
• Canadian\textsuperscript{4} and American\textsuperscript{5} depression guidelines include the option of second-generation antipsychotics alone or as augmentation therapy in patients who have failed first-line antidepressants.
• Second-generation antipsychotics may also help in some anxiety conditions like Generalized Anxiety Disorder.\textsuperscript{6}

\textbf{Bottom-line:} Second-generation antipsychotics appear effective in treating depression when given to augment antidepressants. One antipsychotic (quetiapine) appears effective in treating depression alone but equivalence to antidepressants is uncertain. The evidence has a high risk of bias and adverse events are common.

Authors: Ricky Turgeon, G. Michael Allan MD CCFP

5. APA MDD Guideline: http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1667485#654001

\textit{Tools for Practice} is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practising family physicians who are joined occasionally by a health professional from another medical specialty or health discipline. If you are not a member of the ACFP and would like to receive the TFP emails, please contact subscribetfp@acfp.ca to be added to the distribution list. Archived articles are available on the ACFP website.

This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.